Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 3, Issue 11

June 11 2019

In this Issue

EXCEPTIONAL CASE REPORT
STIMULUS REPORTS
REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
PLATELETS AND THROMBOPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
SYSTEMATIC REVIEW
COMMENTARIES
ERRATA

EXCEPTIONAL CASE REPORT

Emicizumab use in major orthopedic surgery
Clinical Trials & Observations

Craig D. Seaman,Margaret V. Ragni

View Articletitled, Emicizumab use in major orthopedic surgery

STIMULUS REPORTS

Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth
Clinical Trials & Observations

Verena Petzer,Martin Wermke,Piotr Tymoszuk,Dominik Wolf,Markus Seifert,Rıdvan Ovaçin,Sylvia Berger,Dorothea Orth-Höller,Lorin Loacker,Günter Weiss,Hubertus Haas,Uwe Platzbecker,Igor Theurl

View Articletitled, Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth

Supplemental data

Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis
Clinical Trials & Observations

Shiney Seo,Corey Smith,Christopher Fraser,Rajan Patheja,Shaheen P. Shah,Sweera Rehan,Pauline Crooks,Michelle A. Neller,Rajiv Khanna

View Articletitled, Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis

REVIEW ARTICLE

The role of aurora A and polo-like kinases in high-risk lymphomas
Clinical Trials & Observations

Carlos Murga-Zamalloa,Kedar V. Inamdar,Ryan A. Wilcox

View Articletitled, The role of aurora A and polo-like kinases in high-risk lymphomas

CLINICAL TRIALS AND OBSERVATIONS

Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group
Clinical Trials & Observations

Yousif Matloub,Karen R. Rabin,Lingyun Ji,Meenakshi Devidas,Johann Hitzler,Xinxin Xu,Bruce C. Bostrom,Linda C. Stork,Naomi Winick,Julie M. Gastier-Foster,Nyla A. Heerema,Eileen Stonerock,William L. Carroll,Stephen P. Hunger,Paul S. Gaynon

View Articletitled, Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group

Supplemental data

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)
Clinical Trials & Observations

Jun Yin,Betsy LaPlant,Geoffrey L. Uy,Guido Marcucci,William Blum,Richard A. Larson,Richard M. Stone,Sumithra J. Mandrekar

View Articletitled, Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Human peripheral blood DNAM-1^neg NK cells are a terminally differentiated subset with limited effector functions

Kimberley A. Stannard,Sébastien Lemoine,Nigel J. Waterhouse,Frank Vari,Lucienne Chatenoud,Maher K. Gandhi,Ludovic Martinet,Mark J. Smyth,Camille Guillerey

View Articletitled, Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions

Supplemental data

LYMPHOID NEOPLASIA

Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation
Clinical Trials & Observations

Narendranath Epperla,Talha Badar,Aniko Szabo,John Vaughn,Steve Borson,Neeraj Y. Saini,Romil D. Patel,Nirav N. Shah,Mehdi Hamadani,Sairah Ahmed,Amanda F. Cashen,Timothy S. Fenske

View Articletitled, Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation

Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

Neutrophils acquire antigen-presenting cell features after phagocytosis of IgG-opsonized erythrocytes

Sanne M. Meinderts,Gabriella Baker,Stan van Wijk,Boukje M. Beuger,Judy Geissler,Machiel H. Jansen,Anno Saris,Anja ten Brinke,Taco W. Kuijpers,Timo K. van den Berg,Robin van Bruggen

View Articletitled, Neutrophils acquire antigen-presenting cell features after phagocytosis of IgG-opsonized erythrocytes

Supplemental data

PLATELETS AND THROMBOPOIESIS

Murine platelet production is suppressed by S1P release in the hematopoietic niche, not facilitated by blood S1P sensing

Hira Niazi,Nesrine Zoghdani,Ludovic Couty,Alexandre Leuci,Anja Nitzsche,Maria L. Allende,Boubacar Mariko,Rameez Ishaq,Yetki Aslan,Pierre Hadrien Becker,Salomé L. Gazit,Sonia Poirault-Chassac,Benoit Decouture,Veronique Baudrie,Erica De Candia,Mari Kono,Ammar Benarab,Pascale Gaussem,Pierre-Louis Tharaux,Jerold Chun,Sylvain Provot,Najet Debili,Patrice Therond,Richard L. Proia,Christilla Bachelot-Loza,Eric Camerer

View Articletitled, Murine platelet production is suppressed by S1P release in the hematopoietic niche, not facilitated by blood S1P sensing

Supplemental data

THROMBOSIS AND HEMOSTASIS

Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis

Angela C. Weyand,Steve J. Grzegorski,Megan S. Rost,Kari I. Lavik,Allison C. Ferguson,Marzia Menegatti,Catherine E. Richter,Rosanna Asselta,Stefano Duga,Flora Peyvandi,Jordan A. Shavit

View Articletitled, Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis

Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis
Clinical Trials & Observations

Mathivanan Chinnaraj,William Planer,Vittorio Pengo,Nicola Pozzi

View Articletitled, Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis

Supplemental data

TRANSPLANTATION

BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient
Clinical Trials & Observations

Hideki Nakasone,Koji Kawamura,Kimikazu Yakushijin,Akihito Shinohara,Masatsugu Tanaka,Kazuteru Ohashi,Shuichi Ota,Naoyuki Uchida,Takahiro Fukuda,Hirohisa Nakamae,Ken-ichi Matsuoka,Junya Kanda,Tatsuo Ichinohe,Yoshiko Atsuta,Yoshihiro Inamoto,Sachiko Seo,Fumihiko Kimura,Masao Ogata

View Articletitled, BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient

Supplemental data

SYSTEMATIC REVIEW

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
Clinical Trials & Observations

Alessandra Carobbio,Alberto Ferrari,Arianna Masciulli,Arianna Ghirardi,Giovanni Barosi,Tiziano Barbui

View Articletitled, Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis

Supplemental data

COMMENTARIES

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma
Clinical Trials & Observations

Ashraf Z. Badros,Ning Ma,Aaron P. Rapoport,Emily Lederer,Alexander M. Lesokhin

View Articletitled, Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma

Left ventricular diastolic function as a possible predictor of severe carfilzomib-induced cardiovascular events
Clinical Trials & Observations

Yoshiaki Abe,Tetsuya Kobayashi,Kentaro Narita,Hiroki Kobayashi,Akihiro Kitadate,Daisuke Miura,Masami Takeuchi,Kosei Matsue

View Articletitled, Left ventricular diastolic function as a possible predictor of severe carfilzomib-induced cardiovascular events

Supplemental data

ERRATA

Lai C, Ranpura V, Wu C, et al. Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. Blood Adv. 2019;3(7):980-983.

View Articletitled, Lai C, Ranpura V, Wu C, et al. Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. Blood Adv. 2019;3(7):980-983.

Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297.

View Articletitled, Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297.

Cover Image

Cover Image

COVER FIGURE
Single-cell tracking map of natural killer cells. Each line represents the trajectory of an individual CD56^brightCD16⁻ natural killer cell over 40 minutes. Time-lapse microscopy was performed with an Olympus Xcellence IX81 microscope controlled by Xcellence RT software. See the article by Stannard et al.
Front Matter
Editorial Board

All Issues

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy

Phillips NS, Mulrooney DA, Williams AM, et al. Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma. Blood Adv. 2023;7(23):7270-7278.

Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon

A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia

Race and ethnicity reporting and representation in hemophilia clinical trials

Table of Contents

EXCEPTIONAL CASE REPORT

Emicizumab use in major orthopedic surgery
Clinical Trials & Observations

STIMULUS REPORTS

Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth
Clinical Trials & Observations

Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis
Clinical Trials & Observations

REVIEW ARTICLE

The role of aurora A and polo-like kinases in high-risk lymphomas
Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group
Clinical Trials & Observations

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)
Clinical Trials & Observations

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Human peripheral blood DNAM-1^neg NK cells are a terminally differentiated subset with limited effector functions

LYMPHOID NEOPLASIA

Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation
Clinical Trials & Observations

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

Neutrophils acquire antigen-presenting cell features after phagocytosis of IgG-opsonized erythrocytes

PLATELETS AND THROMBOPOIESIS

Murine platelet production is suppressed by S1P release in the hematopoietic niche, not facilitated by blood S1P sensing

THROMBOSIS AND HEMOSTASIS

Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis

Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis
Clinical Trials & Observations

TRANSPLANTATION

BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient
Clinical Trials & Observations

SYSTEMATIC REVIEW

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
Clinical Trials & Observations

COMMENTARIES

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma
Clinical Trials & Observations

Left ventricular diastolic function as a possible predictor of severe carfilzomib-induced cardiovascular events
Clinical Trials & Observations

ERRATA

Lai C, Ranpura V, Wu C, et al. Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. Blood Adv. 2019;3(7):980-983.

Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297.

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

EXCEPTIONAL CASE REPORT

Emicizumab use in major orthopedic surgery Clinical Trials & Observations

STIMULUS REPORTS

Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth Clinical Trials & Observations

Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis Clinical Trials & Observations

REVIEW ARTICLE

The role of aurora A and polo-like kinases in high-risk lymphomas Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group Clinical Trials & Observations

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614) Clinical Trials & Observations

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions

LYMPHOID NEOPLASIA

Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation Clinical Trials & Observations

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

Neutrophils acquire antigen-presenting cell features after phagocytosis of IgG-opsonized erythrocytes

PLATELETS AND THROMBOPOIESIS

Murine platelet production is suppressed by S1P release in the hematopoietic niche, not facilitated by blood S1P sensing

THROMBOSIS AND HEMOSTASIS

Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis

Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis Clinical Trials & Observations

TRANSPLANTATION

BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient Clinical Trials & Observations

SYSTEMATIC REVIEW

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis Clinical Trials & Observations

COMMENTARIES

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma Clinical Trials & Observations

Left ventricular diastolic function as a possible predictor of severe carfilzomib-induced cardiovascular events Clinical Trials & Observations

ERRATA

Lai C, Ranpura V, Wu C, et al. Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. Blood Adv. 2019;3(7):980-983.

Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297.

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Emicizumab use in major orthopedic surgery
Clinical Trials & Observations

Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth
Clinical Trials & Observations

Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis
Clinical Trials & Observations

The role of aurora A and polo-like kinases in high-risk lymphomas
Clinical Trials & Observations

Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group
Clinical Trials & Observations

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)
Clinical Trials & Observations

Human peripheral blood DNAM-1^neg NK cells are a terminally differentiated subset with limited effector functions

Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation
Clinical Trials & Observations

Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis
Clinical Trials & Observations

BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient
Clinical Trials & Observations

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
Clinical Trials & Observations

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma
Clinical Trials & Observations

Left ventricular diastolic function as a possible predictor of severe carfilzomib-induced cardiovascular events
Clinical Trials & Observations